2-氰基-3-萘-1-基-3-苯基丙酸乙酯 | 62875-49-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-氰基-3-萘-1-基-3-苯基丙酸乙酯
• 英文名称: 2-Cyan-3-<1>naphthyl-3-phenyl-propionsaeure-aethylester
• 英文别名: 2-(naphthalen-1-yl(phenyl)methyl)malononitrile；2-cyano-3-[1]naphthyl-3-phenyl-propionic acid ethyl ester；2-Cyan-3-[1]naphthyl-3-phenyl-propionsaeure-aethylester；β-Phenyl-β-(naphthyl-(1))-α-cyan-propionsaeure-aethylester；ethyl 2-cyano-3-(1-naphthyl)-3-phenylpropanoate；ethyl 2-cyano-3-naphthalen-1-yl-3-phenylpropanoate
• CAS: 62875-49-4
• 化学式: C₂₂H₁₉NO₂
• 分子量: 329.398
• InChiKey: KNVTZIDAGQXKIV-UHFFFAOYSA-N

物化性质

• 熔点：
  133 °C(Solv: methanol (67-56-1))
• 沸点：
  526.7±45.0 °C(Predicted)
• 密度：
  1.161±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氰基-3-萘-1-基-3-苯基丙酸乙酯 在 乙醇 、 sodium 作用下， 反应 30.0h， 生成 3-Cyano-1-methyl-4-phenyl-1,2,3,4-tetrahydro-phenanthrene-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Fadda; Badawy; Elmorsy, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1990, vol. 29, # 2, p. 171 - 173

  摘要：

  DOI：
• 作为产物：
  描述：

  α-氰基肉桂酸 在 盐酸 、 乙醚 作用下， 生成 2-氰基-3-萘-1-基-3-苯基丙酸乙酯
  参考文献：
  名称：

  Kohler, Reimer, American Chemical Journal, 1905, vol. 33, p. 340

  摘要：

  DOI：

文献信息

• Use of ER selective NF-kB inhibitors for the treatment of sepsis
  申请人：Caggiano J. Thomas

  公开号：US20050256132A1

  公开（公告）日：2005-11-17

  The present invention provides methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome by modulating NF-κB transcription with ligands that interact with the estrogen receptor, preferably in the absence of classic estrogenic activity. Other aspects of the invention relate to methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome that comprise administering to a patient suffering therefrom an effective amount of a compound of Formula I:

  本发明提供了通过调节与雌激素受体相互作用的配体来调节NF-κB转录，从而治疗脓毒症、全身性炎症反应综合征、严重脓毒症、脓毒性休克和多器官功能障碍综合征的方法，优选在无典型雌激素活性的情况下进行。本发明的其他方面涉及治疗脓毒症、全身性炎症反应综合征、严重脓毒症、脓毒性休克和多器官功能障碍综合征的方法，包括向患有此类病症的患者施用有效量的式I化合物：
• 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
  申请人：Caggiano J. Thomas

  公开号：US20050004164A1

  公开（公告）日：2005-01-06

  This invention provides compounds of formula I or a pharmaceutically acceptable salt thereof that are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.

  本发明提供了I式化合物或其药学上可接受的盐，其对疾病的炎症成分有治疗作用，特别适用于治疗动脉硬化、心肌梗死、充血性心力衰竭、炎症性肠病、关节炎、2型糖尿病以及自身免疫性疾病，如多发性硬化和风湿性关节炎。
• 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use
  申请人：Caggiano J. Thomas

  公开号：US20070299105A1

  公开（公告）日：2007-12-27

  This invention provides compounds of formula I or a pharmaceutically acceptable salt thereof that are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

  这项发明提供了I式化合物或其药学上可接受的盐，可用于治疗疾病的炎症成分，特别是在治疗动脉粥样硬化、心肌梗死、充血性心力衰竭、炎症性肠病、关节炎、2型糖尿病以及自身免疫疾病如多发性硬化和类风湿性关节炎方面特别有用。
• [EN] 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS<br/>[FR] DERIVES D'AMIDES ET D'ESTERS D'ACIDE 2-CYANOPROPANOIQUE ET METHODES D'UTILISATION DESDITS DERIVES
  申请人：WYETH CORP

  公开号：WO2004099150A3

  公开（公告）日：2004-12-23
• Estrogen Receptor Dependent Inhibitors of NF-κB Transcriptional Activation-1 Synthesis and Biological Evaluation of Substituted 2-Cyanopropanoic Acid Derivatives:  Pathway Selective Inhibitors of NF-κB, a Potential Treatment for Rheumatoid Arthritis
  作者：Thomas J. Caggiano、Antony Brazzale、Douglas M. Ho、Christina M. Kraml、Eugene Trybulski、Christopher C. Chadwick、Sue Chippari、Lisa Borges-Marcucci、Amy Eckert、James C. Keith、Thomas Kenney、Douglas C. Harnish

  DOI：10.1021/jm701013k

  日期：2007.11.1

  Pathway selective ligands of the estrogen receptor inhibit transcriptional activation of proinflammatory genes mediated by NF kappa B. Substituted 2-cyanopropanoic acid derivatives were developed leading to the discovery of WAY-204688, an orally active, pathway selective, estrogen receptor dependent anti-inflammatory agent. This propanamide was shown to be orally active in preclinical models of inflammatory diseases, such as rheumatoid arthritis, without the proliferative effect associated with traditional, estrogens.